Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AkzoNobel To Realign Company Portfolios
AkzoNobel is planing to balance its Performance Coatings and Specialty Chemicals portfolios as part of a realignment which will see the launch of two new business units and
AkzoNobel is planing to balance its Performance Coatings and Specialty Chemicals portfolios as part of a realignment which will see the launch of two new business units and
Arpida and Evolva, two Swiss biotech companies, have announced that they intend to merge the two companies subject to definitive agreement and shareholder approval. The company said that
Galapagos has initiated a second phase I clinical trial for GLPG0259, a novel candidate drug being developed for rheumatoid arthritis (RA). The new trial is based on the
MAP Pharmaceuticals has announced plans to present analysis of data from the efficacy portion of the first phase 3 trial of its novel Levadex orally inhaled migraine therapy,
Esperance Pharmaceuticals has begun enrollment and dosing of patients in a phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the candidate from Esperance’s Cationic
GATC Biotech has announced that the mayor Claus Boldt, architect Hans-Peter Engelmann and CEO Peter Pohl, officially initiated the first sod, marking the beginning of the expansion of
Vical’s DNA vaccine against A/H1N1 pandemic influenza (swine flu) has demonstrated robust immune responses in all of vaccinated animals against virus strains isolated from recent outbreaks in three
Acorda Therapeutics has announced the data for interim analysis of two-year efficacy and safety data from phase 3 Fampridine-SR extension study. The open-label extension study for Fampridine-SR trial,
The FDA has removed the clinical hold for Dynavax Technologies’ (Dynavax) Heplisav Investigational New Drug (IND) application in individuals with chronic kidney disease. HEPLISAV is a phase 3
GenScript has signed biology research collaboration with Roche R&D Center (RRDCC), a subsidiary of Roche since early 2009. Under the agreement, GenScript is set to provide assay development